Latest News | Glenmark Pharma Q2 PAT Rises Marginally to Rs 279 Cr
Get latest articles and stories on Latest News at LatestLY. Glenmark Pharmaceuticals on Friday said its profit after tax (PAT) rose marginally to Rs 279 crore for the second quarter ended September 30, 2022.
New Delhi, Nov 11 (PTI) Glenmark Pharmaceuticals on Friday said its profit after tax (PAT) rose marginally to Rs 279 crore for the second quarter ended September 30, 2022.
The Mumbai-based drug firm had reported a PAT of Rs 275 crore in the July-September period of the previous fiscal.
Also Read | HPSC Recruitment 2022: Vacancies Notified for 53 Sub Divisional Engineer Posts, Apply Online at hpsc.gov.in.
Consolidated revenue rose to Rs 3,375 crore in the period under review as against Rs 3,147 crore in the year-ago quarter, Glenmark Pharma said in a regulatory filing.
"We delivered yet another quarter of consistent growth, with our relentless focus on launching differentiated products in our core therapeutic areas," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The company's domestic business recorded strong double-digit growth and Europe business also performed very well in spite of a challenging macro-economic environment, he added.
"We look forward to launching new products across markets and building global scale in our respiratory portfolio," Saldanha said.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)